Rigel Pharma (RIGL) to Present One-Year Efficacy, Safety Results for Fostamatinib in ITP at ASH
Tweet Send to a Friend
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the one-year efficacy and safety results from its FIT Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
